Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical SCT with CD56-Enriched DLI for Lymphoma and Myeloma
NCT03524235Phase 1Completed
- Start
- Jul 2018
- Primary completion
- Nov 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD56-enriched donor lymphocyte infusion in lymphoma, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) (2 arms). Primary endpoint: Rate of Survival at 30 days post-transplantation. Started Jul 2018; status: completed.
02
Drugs
CD56-enriched donor lymphocyte infusion
03
Conditions
lymphomamultiple myeloma (MM)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03524235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524235.